Moawia Mohammed Ali Elhassan, Associate Professor at the University of Gezira, shared a post on LinkedIn:
“PREOPANC-2: A Recently Published Study Challenges the Standard of Care in Pancreatic Cancer
A recently published phase III RCT, compared two neoadjuvant treatments for resectable and borderline resectable pancreatic cancer:
FOLFIRINOX and gemcitabine-based chemoradiotherapy (CRT).
The RT protocol was a hypofractionated regimen of 36 Gy delivered in 15 fractions, concurrent with the second cycle of gemcitabine chemotherapy.
The study found no significant difference in between the two treatment arms (21.9 months for the FOLFIRINOX group vs. 21.3 months for the CRT group.)
FOLFIRINOX was associated with higher rates of grade 3-4 diarrhea, while gemcitabine-based CRT had more cases of leukopenia.
Both regimens are viable options for neoadjuvant treatment in this patient population. The choice may depend on the patient’s specific risk profile and the anticipated side effects.”
Title: Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial
Authors: Quisette P Janssen, Jacob L van Dam, Marlies L van Bekkum, Bert A Bonsing, Hendrik Bos, Koop P Bosscha, Stefan A W Bouwense, Lieke Brouwer-Hol, Anna M E Bruynzeel, Olivier R Busch, Peter-Paul L O Coene, Casper H J van Eijck, Jan Willem B de Groot, Brigitte C M Haberkorn, Ignace H J T de Hingh, Tom M Karsten, Geert Kazemier, Marion B van der Kolk, Mike S L Liem, Olaf J L Loosveld, Saskia A C Luelmo, Misha D P Luyer, Leonie J M Mekenkamp, J Sven D Mieog, Vincent B Nieuwenhuijs, Joost J M E Nuyttens, Gijs A Patijn, Hjalmar C van Santvoort, Martijn W J Stommel, Eva Versteijne, Judith de Vos-Geelen, Roeland F de Wilde, Babs M Zonderhuis, Bronno van der Holt, Marjolein Y V Homs, Geertjan van Tienhoven, Marc G Besselink, Johanna W Wilmink, Bas Groot Koerkamp
More posts featuring Moawia Mohammed Ali Elhassan on OncoDaily